A Study to Assess if Contrast-Enhanced Ultrasound Positively Influences the Selection of Biopsy Sites When Evaluating Transplant Kidneys

Overview

About this study

The purpose of this pilot study is to investigate whether contrast-enhanced ultrasound (CEUS) may help evaluate segmental differences in renal perfusion better than doppler ultrasound and thus help direct a biopsy to the most abnormal part of the renal cortex.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

Ability to provide informed consent
Male and female >18 years
Patients undergoing renal transplant ultrasound-guided percutaneous biopsy within 14 months post transplant including patients undergoing biopsy to evaluate a recent rise in serum creatinine, (so called "for cause" biopsies) and patients undergoing routine protocol (surveillance) biopsies without other evidence of renal dysfunction

Exclusion Criteria

Pregnant women or women who are nursing an infant are not able to participate in this study
Known patent foramen ovale (PFO)
Significant heart disease

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Scottsdale/Phoenix, Ariz. Mayo Clinic principal investigator Jeffry Kriegshauser, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Jeffry Kriegshauser, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials